Trial Profile
An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg Body Weight in Comparison to Filgrastim 5 μg/kg Body Weight in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Merckle
- 12 Jan 2022 This trial has been completed in Romania (Date of the global end of the trial : 08-Jan-2021), according to European Clinical Trials Database record.
- 28 May 2019 This trial has been completed in Croatia, according to European Clinical Trials Database.
- 20 Feb 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.